271 related articles for article (PubMed ID: 21616094)
1. Depletion of GTP pool is not the predominant mechanism by which ribavirin exerts its antiviral effect on Lassa virus.
Ölschläger S; Neyts J; Günther S
Antiviral Res; 2011 Aug; 91(2):89-93. PubMed ID: 21616094
[TBL] [Abstract][Full Text] [Related]
2. The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase.
Leyssen P; Balzarini J; De Clercq E; Neyts J
J Virol; 2005 Feb; 79(3):1943-7. PubMed ID: 15650220
[TBL] [Abstract][Full Text] [Related]
3. The anti-yellow fever virus activity of ribavirin is independent of error-prone replication.
Leyssen P; De Clercq E; Neyts J
Mol Pharmacol; 2006 Apr; 69(4):1461-7. PubMed ID: 16421290
[TBL] [Abstract][Full Text] [Related]
4. Cellular IMPDH enzyme activity is a potential target for the inhibition of Chikungunya virus replication and virus induced apoptosis in cultured mammalian cells.
Khan M; Dhanwani R; Patro IK; Rao PV; Parida MM
Antiviral Res; 2011 Jan; 89(1):1-8. PubMed ID: 21070810
[TBL] [Abstract][Full Text] [Related]
5. Activity of ribavirin against Hantaan virus correlates with production of ribavirin-5'-triphosphate, not with inhibition of IMP dehydrogenase.
Sun Y; Chung DH; Chu YK; Jonsson CB; Parker WB
Antimicrob Agents Chemother; 2007 Jan; 51(1):84-8. PubMed ID: 17060520
[TBL] [Abstract][Full Text] [Related]
6. Antiviral efficacy of EICAR against canine distemper virus (CDV) in vitro.
Dal Pozzo F; Galligioni V; Vaccari F; Gallina L; Battilani M; Scagliarini A
Res Vet Sci; 2010 Apr; 88(2):339-44. PubMed ID: 19781726
[TBL] [Abstract][Full Text] [Related]
7. Antiviral activity and mode of action studies of ribavirin and mycophenolic acid against orthopoxviruses in vitro.
Smee DF; Bray M; Huggins JW
Antivir Chem Chemother; 2001 Nov; 12(6):327-35. PubMed ID: 12018677
[TBL] [Abstract][Full Text] [Related]
8. In vitro combination of amdoxovir and the inosine monophosphate dehydrogenase inhibitors mycophenolic acid and ribavirin demonstrates potent activity against wild-type and drug-resistant variants of human immunodeficiency virus type 1.
Borroto-Esoda K; Myrick F; Feng J; Jeffrey J; Furman P
Antimicrob Agents Chemother; 2004 Nov; 48(11):4387-94. PubMed ID: 15504868
[TBL] [Abstract][Full Text] [Related]
9. 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin) and 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide (EICAR) markedly potentiate the inhibitory effect of 2',3'-dideoxyinosine on human immunodeficiency virus in peripheral blood lymphocytes.
Balzarini J; Lee CK; Schols D; De Clercq E
Biochem Biophys Res Commun; 1991 Jul; 178(2):563-9. PubMed ID: 1650194
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors of the IMPDH enzyme as potential anti-bovine viral diarrhoea virus agents.
Stuyver LJ; Lostia S; Patterson SE; Clark JL; Watanabe KA; Otto MJ; Pankiewicz KW
Antivir Chem Chemother; 2002 Nov; 13(6):345-52. PubMed ID: 12718406
[TBL] [Abstract][Full Text] [Related]
11. Effects of the inhibitors of IMP dehydrogenase, tiazofurin and mycophenolic acid, on glycoprotein metabolism.
Sokoloski JA; Sartorelli AC
Mol Pharmacol; 1985 Dec; 28(6):567-73. PubMed ID: 2867464
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin.
Barnard DL; Day CW; Bailey K; Heiner M; Montgomery R; Lauridsen L; Winslow S; Hoopes J; Li JK; Lee J; Carson DA; Cottam HB; Sidwell RW
Antiviral Res; 2006 Aug; 71(1):53-63. PubMed ID: 16621037
[TBL] [Abstract][Full Text] [Related]
13. Merimepodib, an IMPDH inhibitor, suppresses replication of Zika virus and other emerging viral pathogens.
Tong X; Smith J; Bukreyeva N; Koma T; Manning JT; Kalkeri R; Kwong AD; Paessler S
Antiviral Res; 2018 Jan; 149():34-40. PubMed ID: 29126899
[TBL] [Abstract][Full Text] [Related]
14. Mechanism-based design of inosine 5-monophosphate dehydrogenase inhibitors: synthesis and biological activities of 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide (EICAR) and its derivatives.
Minakawa N; Matsuda A
Curr Med Chem; 1999 Jul; 6(7):615-28. PubMed ID: 10390604
[TBL] [Abstract][Full Text] [Related]
15. Eicar (5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide). A novel potent inhibitor of inosinate dehydrogenase activity and guanylate biosynthesis.
Balzarini J; Karlsson A; Wang L; Bohman C; Horská K; Votruba I; Fridland A; Van Aerschot A; Herdewijn P; De Clercq E
J Biol Chem; 1993 Nov; 268(33):24591-8. PubMed ID: 7901217
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of action of ribavirin in a novel hepatitis C virus replication cell system.
Mori K; Ikeda M; Ariumi Y; Dansako H; Wakita T; Kato N
Virus Res; 2011 Apr; 157(1):61-70. PubMed ID: 21320556
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Junin virus RNA synthesis by an antiviral acridone derivative.
Sepúlveda CS; García CC; Fascio ML; D'Accorso NB; Docampo Palacios ML; Pellón RF; Damonte EB
Antiviral Res; 2012 Jan; 93(1):16-22. PubMed ID: 22027649
[TBL] [Abstract][Full Text] [Related]
18. Inactivation of inosine 5'-monophosphate dehydrogenase by the antiviral agent 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide 5'-monophosphate.
Wang W; Papov VV; Minakawa N; Matsuda A; Biemann K; Hedstrom L
Biochemistry; 1996 Jan; 35(1):95-101. PubMed ID: 8555204
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effects of EICAR on infectious pancreatic necrosis virus replication.
Jashés M; Mlynarz G; De Clercq E; Sandino AM
Antiviral Res; 2000 Jan; 45(1):9-17. PubMed ID: 10774586
[TBL] [Abstract][Full Text] [Related]
20. In vitro study of antiviral activity of mycophenolic acid on Brazilian orthobunyaviruses.
Livonesi MC; Moro de Sousa RL; Moraes Figueiredo LT
Intervirology; 2007; 50(3):204-8. PubMed ID: 17283446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
